WA
RDHL

WFG Advisors’s Redhill Biopharma RDHL Stock Holding History

WFG Advisors’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1
Closed -$10K – 1686
2016
Q3 		$10K Hold
1
– – ﹤0.01% 1129
2016
Q2 		$8K Hold
1
– – ﹤0.01% 1147
2016
Q1 		$9K Hold
1
– – ﹤0.01% 1080
2015
Q4 		$9K Hold
1
– – ﹤0.01% 1107
2015
Q3 		$9K Hold
1
– – ﹤0.01% 1128
2015
Q2 		$12K Buy
+1
New +$15.9K ﹤0.01% 1135

Other funds holding RDHL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

WFG Advisors's RDHL Position: Q4 2016 in Review

WFG Advisors sold out of Redhill Biopharma (RDHL) in Q4 2016, closing a stake of 1 share — an estimated $10K sold.

WFG Advisors first reported a position in RDHL in Q2 2015 and held it in 6 quarters. The position peaked at $12K in Q2 2015. 22 funds tracked by Wall St. Rank hold RDHL as of Q4 2016.

  • WFG Advisors reported no remaining Redhill Biopharma position as of Q4 2016 after selling out during the quarter.
  • WFG Advisors sold 1 Redhill Biopharma share in Q4 2016, an estimated $10K.
  • WFG Advisors first reported a position in Redhill Biopharma in Q2 2015 and held it in 6 quarters.
  • WFG Advisors's Redhill Biopharma position peaked at $12K in Q2 2015.
  • 22 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2016.

Based on WFG Advisors's 13F filing for Q4 2016, filed 1 Mar 2017.